{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:16:42Z","timestamp":1788329802230,"version":"build-2803163510"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    Androgens and the androgen receptor (\n                    <jats:italic toggle=\"yes\">AR<\/jats:italic>\n                    ) play a central role in the development and progression of prostate cancer. While biochanin A (BCA) has been reported to suppress androgen synthesis and overcome resistance to abiraterone and enzalutamide, its direct effects on\n                    <jats:italic toggle=\"yes\">AR<\/jats:italic>\n                    , particularly mutant\n                    <jats:italic toggle=\"yes\">AR<\/jats:italic>\n                    , remain unclear. In this study, we systematically investigated the binding affinity and functional impact of BCA on a panel of clinically relevant\n                    <jats:italic toggle=\"yes\">AR<\/jats:italic>\n                    mutations to identify patient subgroups that may benefit from BCA treatment. Our results demonstrated that BCA exhibits high-binding affinity toward the\n                    <jats:italic toggle=\"yes\">ART877A<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">ARW741C<\/jats:italic>\n                    mutants. Our findings reveal a previously unrecognized mechanism by which BCA directly targets specific AR mutants, in addition to inhibiting androgen biosynthesis. This study provides mechanistic insights into the mutation-selective activity of BCA and supports its potential clinical application in molecularly stratified prostate cancer.\n                  <\/jats:p>","DOI":"10.4103\/aja202632","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:00:14Z","timestamp":1788328814000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Biochanin A inhibits the activity of androgen receptor mutants to suppress the development of prostate cancer"],"prefix":"10.4103","author":[{"given":"Yong-Nan","family":"Chi","sequence":"first","affiliation":[{"name":"Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China"},{"name":"Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng-Long","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Song","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"R1-20260902","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R2-20260902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.04.010","article-title":"Androgens in prostate cancer: a tale that never ends","volume":"516","author":"Hou","year":"2021","journal-title":"Cancer Lett"},{"key":"R3-20260902","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.steroids.2012.03.015","article-title":"Steroid biosynthesis and prostate cancer","volume":"77","author":"Sharifi","year":"2012","journal-title":"Steroids"},{"key":"R4-20260902","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2008.10.008","article-title":"Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks","volume":"55","author":"Isbarn","year":"2009","journal-title":"Eur Urol"},{"key":"R5-20260902","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41585-022-00669-z","article-title":"Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short?","volume":"20","author":"Chen","year":"2023","journal-title":"Nat Rev Urol"},{"key":"R6-20260902","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"key":"R7-20260902","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"R8-20260902","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"R9-20260902","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1172\/JCI98319","article-title":"HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer","volume":"128","author":"Alyamani","year":"2018","journal-title":"J Clin Invest"},{"key":"R10-20260902","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaoncol.2017.3164","article-title":"Association of HSD3B1 genotype with response to androgen-deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer","volume":"4","author":"Hearn","year":"2018","journal-title":"JAMA Oncol"},{"key":"R11-20260902","doi-asserted-by":"crossref","first-page":"100561","DOI":"10.1016\/j.xcrm.2022.100561","article-title":"Inhibiting 3\u03b2HSD1 to eliminate the oncogenic effects of progesterone in prostate cancer","volume":"3","author":"Hou","year":"2022","journal-title":"Cell Rep Med"},{"key":"R12-20260902","doi-asserted-by":"crossref","first-page":"100608","DOI":"10.1016\/j.xcrm.2022.100608","article-title":"Management of prostate cancer by targeting 3\u03b2HSD1 after enzalutamide and abiraterone treatment","volume":"3","author":"Mei","year":"2022","journal-title":"Cell Rep Med"},{"key":"R13-20260902","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s11095-010-0107-9","article-title":"Daidzein effect on hormone refractory prostate cancer in vitro and in vivo compared to genistein and soy extract: potentiation of radiotherapy","volume":"27","author":"Singh-Gupta","year":"2010","journal-title":"Pharm Res"},{"key":"R14-20260902","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","article-title":"Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer","volume":"30","author":"Lenis","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R15-20260902","doi-asserted-by":"crossref","first-page":"17492","DOI":"10.1073\/pnas.1308587110","article-title":"TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer","volume":"110","author":"Nyquist","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R16-20260902","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.synbio.2022.07.005","article-title":"Simulating androgen receptor selection in designer yeast","volume":"7","author":"Zhang","year":"2022","journal-title":"Synth Syst Biotechnol"},{"key":"R17-20260902","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1038\/sj.onc.1209424","article-title":"Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival","volume":"25","author":"Sun","year":"2006","journal-title":"Oncogene"},{"key":"R18-20260902","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/0008-5472.54.65.1","article-title":"Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status","volume":"65","author":"Wetherill","year":"2005","journal-title":"Cancer Res"},{"key":"R19-20260902","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-22-0140","article-title":"Androgen receptor mutations for precision medicine in prostate cancer","volume":"29","author":"Shiota","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"R20-20260902","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/76287","article-title":"Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor","volume":"6","author":"Zhao","year":"2000","journal-title":"Nat Med"},{"key":"R21-20260902","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0960-0760(92)90401-4","article-title":"The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens","volume":"41","author":"Veldscholte","year":"1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R22-20260902","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.2c01164","article-title":"Design, synthesis, and biological evaluation of androgen receptor degrading and antagonizing bifunctional steroidal analogs for the treatment of advanced prostate cancer","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"key":"R23-20260902","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1073\/pnas.0500381102","article-title":"Structural basis for antagonism and resistance of bicalutamide in prostate cancer","volume":"102","author":"Bohl","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R24-20260902","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10822-016-9992-2","article-title":"Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation","volume":"30","author":"Liu","year":"2016","journal-title":"J Comput Aided Mol Des"},{"key":"R25-20260902","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov"},{"key":"R26-20260902","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/mend.11.4.9906","article-title":"Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells","volume":"11","author":"Tan","year":"1997","journal-title":"Mol Endocrinol"},{"key":"R27-20260902","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann Oncol"},{"key":"R28-20260902","doi-asserted-by":"crossref","first-page":"e171199","DOI":"10.1172\/JCI171199","article-title":"Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer","volume":"133","author":"Zhang","year":"2023","journal-title":"J Clin Invest"},{"key":"R29-20260902","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00210-019-01622-5","article-title":"Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines","volume":"392","author":"Fragni","year":"2019","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R30-20260902","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jpba.2016.08.036","article-title":"Structural elucidation of the impurities in enzalutamide bulk drug and the development, validation of corresponding HPLC method","volume":"131","author":"Ma","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"R31-20260902","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"R32-20260902","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1634\/theoncologist.2019-0115","article-title":"Comprehensive analysis of AR alterations in circulating tumor DNA from patients with advanced prostate cancer","volume":"25","author":"Ledet","year":"2020","journal-title":"Oncologist"},{"key":"R33-20260902","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2017.08.012","article-title":"Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201)","volume":"73","author":"Borgmann","year":"2018","journal-title":"Eur Urol"},{"key":"R34-20260902","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cca.2015.12.012","article-title":"Clinical, cytogenetic and molecular analysis of androgen insensitivity syndromes from south Indian cohort and detection and in-silico characterization of androgen receptor gene mutations","volume":"453","author":"Abilash","year":"2016","journal-title":"Clin Chim Acta"},{"key":"R35-20260902","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.7150\/thno.17852","article-title":"Triptolide inhibits the AR signaling pathway to suppress the proliferation of enzalutamide resistant prostate cancer cells","volume":"7","author":"Han","year":"2017","journal-title":"Theranostics"},{"key":"R36-20260902","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1207\/s15327914nc4902_12","article-title":"Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro","volume":"49","author":"Shenouda","year":"2004","journal-title":"Nutr Cancer"},{"key":"R37-20260902","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.juro.2009.07.030","article-title":"Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy","volume":"182","author":"Sharma","year":"2009","journal-title":"J Urol"},{"key":"R38-20260902","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/jcm11010257","article-title":"Biomarkers of castrate resistance in prostate cancer: androgen receptor amplification and T877A mutation detection by multiplex droplet digital PCR","volume":"11","author":"Young","year":"2022","journal-title":"J Clin Med"},{"key":"R39-20260902","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jsbmb.2017.08.016","article-title":"Resveratrol, piceatannol and analogs inhibit activation of both wild-type and T877A mutant androgen receptor","volume":"174","author":"Lundqvist","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R40-20260902","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"R41-20260902","doi-asserted-by":"crossref","first-page":"111608","DOI":"10.1016\/j.ejmech.2019.111608","article-title":"Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants","volume":"182","author":"Yu","year":"2019","journal-title":"Eur J Med Chem"},{"key":"R42-20260902","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-15-0892","article-title":"The effect of F877L and T878A mutations on androgen receptor response to enzalutamide","volume":"15","author":"Prekovic","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"R43-20260902","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/pros.23945","article-title":"A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant ARF876L nuclear import and function","volume":"80","author":"Wu","year":"2020","journal-title":"Prostate"},{"key":"R44-20260902","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/1535-7163.MCT-21-0432","article-title":"(+)-JJ-74-138 is a novel noncompetitive androgen receptor antagonist","volume":"21","author":"Cole","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"R45-20260902","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.canlet.2016.05.018","article-title":"ASC-J9\u00ae suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L","volume":"379","author":"Wang","year":"2016","journal-title":"Cancer Lett"},{"key":"R46-20260902","doi-asserted-by":"crossref","first-page":"e202200548","DOI":"10.1002\/cmdc.202200548","article-title":"Hybrid androgen receptor inhibitors outperform enzalutamide and EPI-001 in in vitro models of prostate cancer drug resistance","volume":"18","author":"Nicolescu","year":"2023","journal-title":"ChemMedChem"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:00:20Z","timestamp":1788328820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":46,"URL":"https:\/\/doi.org\/10.4103\/aja202632","relation":{},"ISSN":["1008-682X","1745-7262"],"issn-type":[{"value":"1008-682X","type":"print"},{"value":"1745-7262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"2025-12-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}